Drugs / Kedrion IVIG 10%
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01581593 | Nov 2012 → Aug 2014 | agammaglobulinemia | Kedrion S.p.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kedrion IVIG 10% | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01581593 ↗ |
| Modality | Protein / enzyme biologic | “Kedrion IVIG 10% is a new preparation of an immunoglobulin G (IgG) solution.” NCT01581593 ↗ |
| Route | Intravenous | “Kedrion IVIG 10% will be given by IV infusion to all study participants.” NCT01581593 ↗ |